Advanced search
1 file | 2.73 MB

A new venue of TNF targeting

Author
Organization
Abstract
The first Food and Drug Administration-(FDA)-approved drugs were small, chemically-manufactured and highly active molecules with possible off-target effects, followed by protein-based medicines such as antibodies. Conventional antibodies bind a specific protein and are becoming increasingly important in the therapeutic landscape. A very prominent class of biologicals are the anti-tumor necrosis factor (TNF) drugs that are applied in several inflammatory diseases that are characterized by dysregulated TNF levels. Marketing of TNF inhibitors revolutionized the treatment of diseases such as Crohn's disease. However, these inhibitors also have undesired effects, some of them directly associated with the inherent nature of this drug class, whereas others are linked with their mechanism of action, being pan-TNF inhibition. The effects of TNF can diverge at the level of TNF format or receptor, and we discuss the consequences of this in sepsis, autoimmunity and neurodegeneration. Recently, researchers tried to design drugs with reduced side effects. These include molecules with more specificity targeting one specific TNF format or receptor, or that neutralize TNF in specific cells. Alternatively, TNF-directed biologicals without the typical antibody structure are manufactured. Here, we review the complications related to the use of conventional TNF inhibitors, together with the anti-TNF alternatives and the benefits of selective approaches in different diseases.
Keywords
TUMOR-NECROSIS-FACTOR, INFLAMMATORY-BOWEL-DISEASE, EXPERIMENTAL, AUTOIMMUNE ENCEPHALOMYELITIS, REGULATORY T-CELLS, COLLAGEN-INDUCED, ARTHRITIS, NF-KAPPA-B, PLACEBO-CONTROLLED TRIAL, RECEPTOR FUSION, PROTEIN, TRAUMATIC BRAIN-INJURY, CENTRAL-NERVOUS-SYSTEM, tumor necrosis factor (TNF), TNF receptor (TNFR), biologicals

Downloads

  • 3053 18Steeland.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 2.73 MB

Citation

Please use this url to cite or link to this publication:

Chicago
Steeland, Sophie, Claude Libert, and Roosmarijn Vandenbroucke. 2018. “A New Venue of TNF Targeting.” International Journal of Molecular Sciences 19 (5).
APA
Steeland, S., Libert, C., & Vandenbroucke, R. (2018). A new venue of TNF targeting. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 19(5).
Vancouver
1.
Steeland S, Libert C, Vandenbroucke R. A new venue of TNF targeting. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2018;19(5).
MLA
Steeland, Sophie, Claude Libert, and Roosmarijn Vandenbroucke. “A New Venue of TNF Targeting.” INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 19.5 (2018): n. pag. Print.
@article{8582069,
  abstract     = {The first Food and Drug Administration-(FDA)-approved drugs were small, chemically-manufactured and highly active molecules with possible off-target effects, followed by protein-based medicines such as antibodies. Conventional antibodies bind a specific protein and are becoming increasingly important in the therapeutic landscape. A very prominent class of biologicals are the anti-tumor necrosis factor (TNF) drugs that are applied in several inflammatory diseases that are characterized by dysregulated TNF levels. Marketing of TNF inhibitors revolutionized the treatment of diseases such as Crohn's disease. However, these inhibitors also have undesired effects, some of them directly associated with the inherent nature of this drug class, whereas others are linked with their mechanism of action, being pan-TNF inhibition. The effects of TNF can diverge at the level of TNF format or receptor, and we discuss the consequences of this in sepsis, autoimmunity and neurodegeneration. Recently, researchers tried to design drugs with reduced side effects. These include molecules with more specificity targeting one specific TNF format or receptor, or that neutralize TNF in specific cells. Alternatively, TNF-directed biologicals without the typical antibody structure are manufactured. Here, we review the complications related to the use of conventional TNF inhibitors, together with the anti-TNF alternatives and the benefits of selective approaches in different diseases.},
  articleno    = {1442},
  author       = {Steeland, Sophie and Libert, Claude and Vandenbroucke, Roosmarijn},
  issn         = {1422-0067},
  journal      = {INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES},
  language     = {eng},
  number       = {5},
  pages        = {55},
  title        = {A new venue of TNF targeting},
  url          = {http://dx.doi.org/10.3390/ijms19051442},
  volume       = {19},
  year         = {2018},
}

Altmetric
View in Altmetric
Web of Science
Times cited: